Refine
Document Type
- Article (2) (remove)
Language
- English (2)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2)
Institute
- Medizin (1)
- Wirtschaftswissenschaften (1)
What are the effects of the GDPR on consumer apps? This article presents an analysis of app behavior before and after the regulatory change in data protection in Europe. Based on long-term data collection, we present differences in app permission use and expressed user concerns and discuss their implications. In May 2018, the General Data Protection Regulation (GDPR) changed the data protection obligations of the information industry with the European Union users substantially. One should expect to find changes in code, program behavior and data collection activities. To investigate this expectation, we analyzed data about Android apps request and use of permissions to access sensitive group of data on smartphones, and collected user reviews. Our data shows an overall reduction of both permissions used and of expressed user concern. However, in some areas apps have increased access or user complaints while in addition, many apps carry with them several unused access privileges.
The tyrosine kinase inhibitor sunitinib is used as first‐line therapy in patients with metastasized renal cell carcinoma (mRCC), given in fixed‐dose regimens despite its high variability in pharmacokinetics (PKs). Interindividual variability of drug exposure may be responsible for differences in response. Therefore, dosing strategies based on pharmacokinetic/pharmacodynamic (PK/PD) models may be useful to optimize treatment. Plasma concentrations of sunitinib, its active metabolite SU12662, and the soluble vascular endothelial growth factor receptors sVEGFR‐2 and sVEGFR‐3, were measured in 26 patients with mRCC within the EuroTARGET project and 21 patients with metastasized colorectal cancer (mCRC) from the C‐II‐005 study. Based on these observations, PK/PD models with potential influence of genetic predictors were developed and linked to time‐to‐event (TTE) models. Baseline sVEGFR‐2 levels were associated with clinical outcome in patients with mRCC, whereas active drug PKs seemed to be more predictive in patients with mCRC. The models provide the basis of PK/PD‐guided strategies for the individualization of anti‐angiogenic therapies.